Bolt Biotherapeutics to Present at Stifel 2022 Healthcare Conference

Rhea-AI Summary

Bolt Biotherapeutics (Nasdaq: BOLT) will participate in the Stifel 2022 Healthcare Conference on Nov. 16, 2022, at 1:15 p.m. EST in New York. The event will feature a fireside chat with management, and a live webcast can be accessed on Bolt's website. The company is known for developing innovative immuno-oncology therapeutics, including BDC-1001 and BDC-3042, which target HER2 and modulate myeloid biology, respectively. Archived replays will be available for 30 days post-event.

REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will participate in a fireside chat at the Stifel 2022 Healthcare Conference on Wednesday, Nov. 16, 2022, at 1:15 p.m. EST (10:15 a.m. PST) in New York, New York.

A live webcast of the fireside chat will be available on the Events and Presentations page of Bolt’s website at www.boltbio.com. Archived replays will be available for 30 days following the event.

About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer. Bolt Biotherapeutics’ pipeline candidates are built on the Company’s deep expertise in myeloid biology and cancer drug development. The Company’s pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody and multiple Boltbody ISAC collaboration programs. Bolt Biotherapeutics is currently progressing BDC-1001 through a Phase 1/2 dose-escalation clinical trial, as a monotherapy and in combination with Bristol Myers Squibb’s immune checkpoint inhibitor, Opdivo^® (nivolumab), in a variety of HER2-expressing solid tumors. Bolt Biotherapeutics is advancing BDC-3042, an agonist antibody targeting Dectin-2, through IND-enabling studies. In preclinical development, BDC-3042 demonstrated the ability to convert tumor-supportive macrophages to tumor-destructive macrophages. Bolt Biotherapeutics is leveraging its ability to engineer and optimize novel applications of its Boltbody ISACs to develop multiple immuno-oncology candidates through strategic collaborations with leading biopharmaceutical companies. For more information, please visit https://www.boltbio.com/.

Investor Relations and Media Contacts:
Karen L. Bergman
Vice President, Communications and Investor Relations
Bolt Biotherapeutics, Inc.
650-665-9295
kbergman@boltbio.com

Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah.mccabe@sternir.com

David Schull
Russo Partners, LLC
646-942-5631
david.schull@russopartnersllc.com

FAQ

When will Bolt Biotherapeutics participate in the Stifel 2022 Healthcare Conference?

Bolt Biotherapeutics will participate in the Stifel 2022 Healthcare Conference on Nov. 16, 2022, at 1:15 p.m. EST.

Where can I watch the fireside chat for Bolt Biotherapeutics?

The fireside chat for Bolt Biotherapeutics can be watched live on their website during the conference.

What is the focus of Bolt Biotherapeutics' pipeline?

Bolt Biotherapeutics focuses on developing novel immuno-oncology therapeutics for cancer treatment.

How long will the archived replay of the Bolt Biotherapeutics event be available?

The archived replay of the Bolt Biotherapeutics event will be available for 30 days after the conference.

What are the key product candidates of Bolt Biotherapeutics?

Key product candidates include BDC-1001, a HER2-targeting antibody, and BDC-3042, a myeloid-modulating antibody.